Jeffrey Chen, MD
Child & Adolescent Psychiatry · Campbell
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Chen’s office at (408) 622-1661 to ask if they take your plan before you enroll.
California Medical Board record
Licence A127688 · Current
Licensed to practise in California · since 2013 · expires 2027-09-30 · Northwestern University Feinberg School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$27,612
Pharmacies billed $27,612 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 99) in 2024. At or below the middle of the specialty; the typical neuropsychiatry clinician is at 0%.
63 generic and 36 brand-name prescriptions · $27,612 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rexulti | 12 | $15,634 | $1,303 |
| Mydayis | 24 | $7,131 | $297 |
| Desvenlafaxine Succinate Er | 11 | $2,999 | $273 |
| Buspirone | 16 | $417 | $26 |
| Escitalopram | 13 | $30 | $2 |
See all 6 drugs
| Rexulti | 12 | $15,634 | $1,303 |
| Mydayis | 24 | $7,131 | $297 |
| Desvenlafaxine Succinate Er | 11 | $2,999 | $273 |
| Buspirone | 16 | $417 | $26 |
| Escitalopram | 13 | $30 | $2 |
| Lamotrigine | 17 | $27 | $2 |
Year by year
| 2024 | 99 | None | 0% (0) | 36% | $27,612 |
| 2023 | 86 | None | 0% (0) | 41% | $30,493 |
| 2022 | 48 | None | 0% (0) | 71% | $27,183 |
| 2021 | 40 | None | 0% (0) | 68% | $23,054 |
| 2020 | 36 | None | 0% (0) | 67% | $20,101 |
| 2019 | 45 | None | 0% (0) | 60% | $17,897 |
| 2018 | 102 | None | 0% (0) | 33% | $32,759 |
| 2017 | 80 | None | 0% (0) | None | $6,631 |
| 2016 | 143 | 12 | 0% (0) | 10% | $20,055 |
| 2015 | 62 | 19 | 0% (0) | None | $8,493 |
| 2013 | 54 | None | 0% (0) | 22% | $4,537 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Rexulti | 11 | $13,824 | $1,257 |
| Mydayis | 22 | $8,793 | $400 |
| Desvenlafaxine Succinate Er | 11 | $2,376 | $216 |
| Buspirone | 11 | $574 | $52 |
| Lamotrigine | 18 | $184 | $10 |
2022: 2 drugs
| Rexulti | 13 | $15,340 | $1,180 |
| Mydayis | 21 | $7,466 | $356 |
2021: 1 drug
| Rexulti | 14 | $15,413 | $1,101 |
2020: 2 drugs
| Rexulti | 12 | $12,426 | $1,036 |
| Vyvanse | 12 | $3,794 | $316 |
2019: 2 drugs
| Rexulti | 11 | $11,231 | $1,021 |
| Vyvanse | 12 | $3,582 | $299 |
2018: 5 drugs
| Rexulti | 12 | $12,781 | $1,065 |
| Vyvanse | 12 | $3,530 | $294 |
| Desvenlafaxine Succinate Er | 11 | $2,603 | $237 |
| Buspirone | 13 | $292 | $22 |
| Clonazepam | 11 | $38 | $3 |
2016: 5 drugs
| Divalproex Sodium Er | 16 | $1,576 | $99 |
| Haloperidol | 17 | $863 | $51 |
| Oxcarbazepine | 13 | $387 | $30 |
| Fluoxetine | 14 | $234 | $17 |
| Lamotrigine | 22 | $115 | $5 |
2013: 2 drugs
| Levothyroxine | 11 | $103 | $9 |
| Lisinopril | 11 | $79 | $7 |
Money from drug and device companies
$336 in 2025
| 2025 | 5 | 12 | None | $336 |
| 2024 | 4 | 8 | None | $195 |
| 2023 | 2 | 3 | None | $100 |
| 2022 | 1 | 1 | None | $18 |
| 2021 | 1 | 1 | None | $16 |
| 2020 | 1 | 1 | None | $25 |
| 2019 | 1 | 3 | None | $51 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Axsome Therapeutics | Auvelity | $191 | 7 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $41 | 2 payments
|
| Boston Scientific | Wavewriter Alpha Prime 16 | $39 | 1 payment
|
| Lundbeck | Rexulti | $34 | 1 payment
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $31 | 1 payment
|
See all 12 published payments
| Axsome Therapeutics | Meals · 2025-12-18 | Auvelity | $33 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-06 | Trintellix | $24 |
| Axsome Therapeutics | Meals · 2025-10-02 | Auvelity | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-15 | Trintellix | $17 |
| Axsome Therapeutics | Meals · 2025-08-07 | Auvelity | $32 |
| Axsome Therapeutics | Meals · 2025-07-10 | Auvelity | $25 |
| Axsome Therapeutics | Meals · 2025-06-26 | Auvelity | $31 |
| Axsome Therapeutics | Meals · 2025-04-24 | Auvelity | $28 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-04-17 | Caplyta | $31 |
| Lundbeck | Meals · 2025-03-26 | Rexulti | $34 |
| Axsome Therapeutics | Meals · 2025-02-13 | Auvelity | $21 |
| Boston Scientific | Meals · 2025-02-08 | Wavewriter Alpha Prime 16 | $39 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $195
| Axsome Therapeutics | Auvelity | $69 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $55 | 3 payments
|
| Vanda Pharmaceuticals | Fanapt | $51 | 2 payments
|
| Supernus Pharmaceuticals | Qelbree | $20 | 1 payment
|
2023: $100
| Iti | Caplyta | $79 | 2 payments
|
| Supernus Pharmaceuticals | Qelbree | $20 | 1 payment
|
2022: $18
| Iti | Caplyta | $18 | 1 payment
|
2021: $16
| Supernus Pharmaceuticals | Qelbree | $16 | 1 payment
|
2020: $25
| Ironshore Pharmaceuticals | Jornay Pm | $25 | 1 payment
|
2019: $51
| Takeda Pharmaceuticals U.S.A. | Trintellix | $51 | 3 payments
|
Professional record
- NPI
- 1548402019
- Licence
- CA A127688California A127688: Current · expires 2027-09-30
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 2084P0804X (2084P0804X); Psychiatry (2084P0800X)
- Mailing address
- 51 E Campbell Ave Ste 170, Campbell, CA, 95008
- NPI first listed
- 2009-03-30
- NPI last updated
- 2016-04-06
This is when the NPI record was last certified, not a medical board exam.